Al Sharie S, Abu Laban D, Al-Hussaini M (2023) Decoding diffuse midline gliomas: a comprehensive review of pathogenesis, diagnosis and treatment. Cancers 15(19). https://doi.org/10.3390/cancers15194869

Alpen K, Vajdic CM, MacInnis RJ, Milne RL, Koh ES, Hovey E, Harrup R, Bruinsma F, Nguyen TL, Li S, Joseph D, Benke G, Dugué PA, Southey MC, Giles GG, Rosenthal M, Drummond KJ, Nowak AK, Hopper JL, Kapuscinski M, Makalic E (2023) Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26. Neuro Oncol 25(7):1355–1365. https://doi.org/10.1093/neuonc/noac279

Article  PubMed  Google Scholar 

Anitha K, Posinasetty B, Naveen Kumari K, Chenchula S, Padmavathi R, Prakash S, Radhika C (2024) Liquid biopsy for precision diagnostics and therapeutics. Clin Chim Acta Int J Clin Chem 554:117746. https://doi.org/10.1016/j.cca.2023.117746

Arvanitis CD, Ferraro GB, Jain RK (2020) The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer 20(1):26–41. https://doi.org/10.1038/s41568-019-0205-x

Article  CAS  PubMed  Google Scholar 

Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O’Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL (2020) Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma: a pilot prospective study. Clini Cancer Res Official J Am Assoc Cancer Res 26(2):397–407. https://doi.org/10.1158/1078-0432.Ccr-19-2533

Article  CAS  Google Scholar 

Bagley SJ, Till J, Abdalla A, Sangha HK, Yee SS, Freedman J, Black TA, Hussain J, Binder ZA, Brem S, Desai AS, O'Rourke DM, Long Q, Nabavizadeh SA, Carpenter EL (2021) Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma. Neuro-oncology Adv 3(1):vdab011. https://doi.org/10.1093/noajnl/vdab011

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih l M, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA, Jr (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6 (224):224ra224. https://doi.org/10.1126/scitranslmed.3007094

Bohers E, Viailly PJ, Jardin F (2021) cfDNA Sequencing: technological approaches and bioinformatic issues. Pharmaceuticals (Basel, Switzerland) 14(6). https://doi.org/10.3390/ph14060596

Bronkhorst AJ, Ungerer V, Holdenrieder S (2019) The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif 17:100087. https://doi.org/10.1016/j.bdq.2019.100087

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butler TM, Spellman PT, Gray J (2017) Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Dev 42:14–21. https://doi.org/10.1016/j.gde.2016.12.003

Article  CAS  PubMed  Google Scholar 

Bv H, Jolly MK (2024) Proneural-mesenchymal antagonism dominates the patterns of phenotypic heterogeneity in glioblastoma. iScience 27(3):109184. https://doi.org/10.1016/j.isci.2024.109184

Carpenter EL, Bagley SJ (2022) Clinical utility of plasma cell-free DNA in gliomas. Neuro-oncol Adv 4(Suppl 2):ii41–ii44. https://doi.org/10.1093/noajnl/vdac014

Chai R, Fang S, Pang B, Liu Y, Wang Y, Zhang W, Jiang T (2022) Molecular pathology and clinical implications of diffuse glioma. Chin Med J 135(24):2914–2925. https://doi.org/10.1097/cm9.0000000000002446

Article  CAS  PubMed  Google Scholar 

Chen M, Zhao H (2019) Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics 13(1):34. https://doi.org/10.1186/s40246-019-0220-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng F, Su L, Qian C (2016) Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget 7(30):48832–48841. https://doi.org/10.18632/oncotarget.9453

Chicard M, Colmet-Daage L, Clement N, Danzon A, Bohec M, Bernard V, Baulande S, Bellini A, Deveau P, Pierron G, Lapouble E, Janoueix-Lerosey I, Peuchmaur M, Corradini N, Defachelles AS, Valteau-Couanet D, Michon J, Combaret V, Delattre O, Schleiermacher G (2018) Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma. Clin Cancer Res Offic J Am Assoc Cancer Res 24(4):939–949. https://doi.org/10.1158/1078-0432.Ccr-17-1586

Article  CAS  Google Scholar 

Cimmino F, Lasorsa VA, Vetrella S, Iolascon A, Capasso M (2020) A targeted gene panel for circulating tumor DNA sequencing in neuroblastoma. Front Oncol 10:596191. https://doi.org/10.3389/fonc.2020.596191

Article  PubMed  PubMed Central  Google Scholar 

Coakley M, Villacampa G, Sritharan P, Swift C, Dunne K, Kilburn L, Goddard K, Pipinikas C, Rojas P, Emmett W, Hall P, Harper-Wynne C, Hickish T, Macpherson I, Okines A, Wardley A, Wheatley D, Waters S, Palmieri C, Winter M, Cutts RJ, Garcia-Murillas I, Bliss J, Turner NC (2023) Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple negative breast cancer. Clin Cancer Res Offic J Am Assoc Cancer Res. https://doi.org/10.1158/1078-0432.Ccr-23-2326

Article  Google Scholar 

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science (New York, NY) 359(6378):926–930. https://doi.org/10.1126/science.aar3247

Article  CAS  Google Scholar 

Connolly ID, Li Y, Gephart MH, Nagpal S (2016) The “Liquid Biopsy”: the role of circulating DNA and RNA in central nervous system tumors. Curr Neurol Neurosci Rep 16(3):25. https://doi.org/10.1007/s11910-016-0629-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Constâncio V, Barros-Silva D, Jerónimo C, Henrique R (2019) Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies. Expert Rev Mol Diagn 19(5):367–375. https://doi.org/10.1080/14737159.2019.1604224

Article  CAS  PubMed  Google Scholar 

Dai L, Jing Z, Zhu Y, Deng K, Ma L (2023a) Genome-wide analysis of circulating tumor DNA methylation profiles in cerebrospinal fluid: a clinical trial of oncolytic virus for glioblastoma. Am J Cancer Res 13(12):5950–5965

CAS  PubMed  PubMed Central  Google Scholar 

Dai L, Liu Z, Zhu Y, Ma L (2023b) Genome-wide methylation analysis of circulating tumor DNA: a new biomarker for recurrent glioblastom. Heliyon 9(3):e14339. https://doi.org/10.1016/j.heliyon.2023.e14339

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dao J, Conway PJ, Subramani B, Meyyappan D, Russell S, Mahadevan D (2023) Using cfDNA and ctDNA as oncologic markers: a path to clinical validation. Int J Molec Sci 24(17). https://doi.org/10.3390/ijms241713219

De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839. https://doi.org/10.1038/ncomms9839

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diaz M, Chudsky S, Pentsova E, Miller AM (2024) Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors. Transl Oncol 41:101881. https://doi.org/10.1016/j.tranon.2024.101881

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duan H, Hu JL, Chen ZH, Li JH, He ZQ, Wang ZN, Zhang GH, Guo XY, Liang L, Mou YG (2020) Assessment of circulating tumor DNA in cerebrospinal fluid by whole exome sequencing to detect genomic alterations of glioblastoma. Chin Med J 133(12):1415–1421. https://doi.org/10.1097/cm9.0000000000000843

Article  CAS  PubMed  PubMed Central  Google Scholar 

Escudero L, Martínez-Ricarte F, Seoane J (2021) ctDNA-based liquid biopsy of cerebrospinal fluid in brain cancer. Cancers 13(9). https://doi.org/10.3390/cancers13091989

Estival A, Sanz C, Ramirez JL, Velarde JM, Domenech M, Carrato C, de Las PR, Gil-Gil M, Sepúlveda J, Armengol R, Cardiel I, Berrocal A, Luque R, Herrero A, Balana C (2019) Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. Sci Rep 9(1):11125. https://doi.org/10.1038/s41598-019-47642-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fisher JP, Adamson DC (2021) Current FDA-Approved therapies for high-grade malignant gliomas. Biomedicines 9(3). https://doi.org/10.3390/biomedicines9030324

Fontanilles M, Marguet F, Beaussire L, Magne N, Pépin LF, Alexandru C, Tennevet I, Hanzen C, Langlois O, Jardin F, Laquerrière A, Sarafan-Vasseur N, Di Fiore F, Clatot F (2020) Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. Acta Neuropathol Commun 8(1):179. https://doi.org/10.1186/s40478-020-01057-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujioka Y, Hata N, Akagi Y, Kuga D, Hatae R, Sangatsuda Y, Michiwaki Y, Amemiya T, Takigawa K, Funakoshi Y, Sako A, Iwaki T, Iihara K, Mizoguchi M (2021) Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid. J Neurooncol 152(1):47–54. https://doi.org/10.1007/s11060-020-03682-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujita Y, Nunez-Rubiano L, Dono A, Bellman A, Shah M, Rodriguez JC, Putluri V, Kamal AHM, Putluri N, Riascos RF, Zhu JJ, Esquenazi Y, Ballester LY (2022) IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas. J Neuro-oncol 159(2):261–270. https://doi.org/10.1007/s11060-022-04060-1

Guo W, Jin L, Liang J, Lin G, Zheng J, Zhou D, Zhan S, Sun H, Jiang X (2022) Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients. Clin Chim Acta Int J Clin Chem 534:81–92.